Jakob Dal

1.1k total citations
37 papers, 741 citations indexed

About

Jakob Dal is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery and Molecular Biology. According to data from OpenAlex, Jakob Dal has authored 37 papers receiving a total of 741 indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Endocrinology, Diabetes and Metabolism, 11 papers in Surgery and 7 papers in Molecular Biology. Recurrent topics in Jakob Dal's work include Pituitary Gland Disorders and Treatments (23 papers), Growth Hormone and Insulin-like Growth Factors (22 papers) and Adrenal and Paraganglionic Tumors (8 papers). Jakob Dal is often cited by papers focused on Pituitary Gland Disorders and Treatments (23 papers), Growth Hormone and Insulin-like Growth Factors (22 papers) and Adrenal and Paraganglionic Tumors (8 papers). Jakob Dal collaborates with scholars based in Denmark, Netherlands and Norway. Jakob Dal's co-authors include Jens Otto Lunde Jørgensen, Marianne Andersen, Ulla Feldt‐Rasmussen, Olaf M. Dekkers, Henrik Toft Sørensen, Eigil Husted Nielsen, Lars Pedersen, Lars Kristensen, Peter Laurberg and Peter Vestergaard and has published in prestigious journals such as The Journal of Clinical Endocrinology & Metabolism, Bone and Molecular Therapy.

In The Last Decade

Jakob Dal

35 papers receiving 723 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jakob Dal Denmark 14 528 219 128 74 65 37 741
Julie Silverstein United States 9 438 0.8× 157 0.7× 113 0.9× 51 0.7× 60 0.9× 27 627
Murray B. Gordon United States 20 764 1.4× 357 1.6× 119 0.9× 108 1.5× 48 0.7× 59 1.2k
Alessandro Piovesan Italy 18 646 1.2× 323 1.5× 155 1.2× 52 0.7× 273 4.2× 47 1.1k
A. Pia Italy 18 817 1.5× 750 3.4× 130 1.0× 51 0.7× 89 1.4× 26 1.1k
Sabrina Chiloiro Italy 20 985 1.9× 374 1.7× 159 1.2× 85 1.1× 69 1.1× 93 1.2k
Marianne S. Elston New Zealand 18 505 1.0× 322 1.5× 213 1.7× 79 1.1× 134 2.1× 59 972
Gabriel Obiols Spain 15 763 1.4× 296 1.4× 137 1.1× 119 1.6× 114 1.8× 36 976
Davide Giordano Italy 15 461 0.9× 460 2.1× 132 1.0× 68 0.9× 97 1.5× 43 942
Holger Franz Germany 9 472 0.9× 227 1.0× 70 0.5× 48 0.6× 110 1.7× 24 682

Countries citing papers authored by Jakob Dal

Since Specialization
Citations

This map shows the geographic impact of Jakob Dal's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jakob Dal with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jakob Dal more than expected).

Fields of papers citing papers by Jakob Dal

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jakob Dal. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jakob Dal. The network helps show where Jakob Dal may publish in the future.

Co-authorship network of co-authors of Jakob Dal

This figure shows the co-authorship network connecting the top 25 collaborators of Jakob Dal. A scholar is included among the top collaborators of Jakob Dal based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jakob Dal. Jakob Dal is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Vestergaard, Peter, et al.. (2024). Semaglutide as a promising treatment for hypothalamic obesity: a six-month case series on four females with craniopharyngioma. Pituitary. 27(5). 723–730. 8 indexed citations
2.
Dal, Jakob, et al.. (2024). Health Literacy Among Young People With Type 1 Diabetes: A Qualitative Study of Patient Involvement. Diabetes Spectrum. 38(1). 41–48. 1 indexed citations
3.
Andersen, Marianne, et al.. (2024). The changing landscape of acromegaly – an epidemiological perspective. Reviews in Endocrine and Metabolic Disorders. 25(4). 691–705. 7 indexed citations
4.
5.
Vestergaard, Peter, et al.. (2024). Is bioimpedance analysis feasible in transgender men?. Clinical Nutrition Open Science. 57. 99–108.
6.
Madsen, Michael, et al.. (2023). Ectopic lipid deposition and insulin resistance in patients with GH disorders before and after treatment. European Journal of Endocrinology. 188(1). 78–85. 8 indexed citations
7.
Dal, Jakob, Arvind Y. M. Sundaram, Annika E. Michelsen, et al.. (2023). Gene expression profiling of subcutaneous adipose tissue reveals new biomarkers in acromegaly. European Journal of Endocrinology. 188(3). 310–321. 4 indexed citations
8.
Dal, Jakob, et al.. (2023). Whole-Body and Forearm Muscle Protein Metabolism in Patients With Acromegaly Before and After Treatment. The Journal of Clinical Endocrinology & Metabolism. 108(9). e671–e678. 4 indexed citations
9.
Dal, Jakob, et al.. (2023). Bone parameters in T1D and T2D assessed by DXA and HR-pQCT – A cross-sectional study: The DIAFALL study. Bone. 172. 116753–116753. 23 indexed citations
10.
Dal, Jakob, Jesper Karmisholt, Ulla Feldt‐Rasmussen, et al.. (2022). Sex difference in patients with controlled acromegaly—A multicentre survey. Clinical Endocrinology. 98(1). 74–81. 8 indexed citations
11.
Dal, Jakob, Michael Madsen, Astrid Johannesson Hjelholt, et al.. (2021). Reversible insulin resistance in muscle and fat unrelated to the metabolic syndrome in patients with acromegaly. EBioMedicine. 75. 103763–103763. 29 indexed citations
12.
Dal, Jakob, et al.. (2019). Fibroblast Activation Protein is a GH Target: A Prospective Study of Patients with Acromegaly Before and After Treatment. The Journal of Clinical Endocrinology & Metabolism. 105(1). 106–115. 11 indexed citations
13.
Dal, Jakob, et al.. (2019). Falls and Fractures in Diabetes—More than Bone Fragility. Current Osteoporosis Reports. 17(3). 147–156. 34 indexed citations
14.
Dal, Jakob, et al.. (2019). Diabetes and fractures: new evidence of atypical femoral fractures?. Osteoporosis International. 31(3). 447–455. 18 indexed citations
15.
Dal, Jakob, Marianne Klose, Ansgar Heck, et al.. (2017). Targeting either GH or IGF-I during somatostatin analogue treatment in patients with acromegaly: a randomized multicentre study. European Journal of Endocrinology. 178(1). 65–74. 17 indexed citations
16.
Muhammad, Ammar, A. J. van der Lely, Patric J. D. Delhanty, et al.. (2016). What is the efficacy of switching to weekly pegvisomant in acromegaly patients well controlled on combination therapy?. European Journal of Endocrinology. 174(5). 663–667. 10 indexed citations
17.
Dal, Jakob, Katrine Lundby Høyer, Steen B. Pedersen, et al.. (2016). Growth Hormone and Insulin Signaling in Acromegaly: Impact of Surgery Versus Somatostatin Analog Treatment. The Journal of Clinical Endocrinology & Metabolism. 101(10). 3716–3723. 9 indexed citations
18.
Dal, Jakob, Edward O. List, Jens Otto Lunde Jørgensen, & Darlene E. Berryman. (2015). Glucose and Fat Metabolism in Acromegaly: From Mice Models to Patient Care. Neuroendocrinology. 103(1). 96–105. 27 indexed citations
19.
20.
Graversen, Jonas Heilskov, Pia Svendsen, Frederik Dagnæs‐Hansen, et al.. (2012). Targeting the Hemoglobin Scavenger receptor CD163 in Macrophages Highly Increases the Anti-inflammatory Potency of Dexamethasone. Molecular Therapy. 20(8). 1550–1558. 106 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Julie Silverstein Breakdown of academic impact, for papers by Murray B. Gordon Breakdown of academic impact, for papers by Alessandro Piovesan Breakdown of academic impact, for papers by A. Pia Breakdown of academic impact, for papers by Sabrina Chiloiro Breakdown of academic impact, for papers by Marianne S. Elston Breakdown of academic impact, for papers by Gabriel Obiols Breakdown of academic impact, for papers by Davide Giordano Breakdown of academic impact, for papers by Holger Franz
Rankless by CCL
2026